| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -98,539 | -83,273 | 119,244 | -149,669 |
| Depreciation and amortization | 688 | 721 | 661 | 1,318 |
| Net accretion of discounts on marketable securities | 1,211 | 1,524 | 1,982 | 6,470 |
| Stock-based compensation | 14,536 | 11,793 | 12,217 | 22,105 |
| Amortization of right-of-use assets | 455 | 476 | 369 | 1,048 |
| Accounts receivable | NaN | 0 | NaN | NaN |
| Prepaid expenses and other assets | -3,025 | 5,562 | -192 | 2,470 |
| Accounts payable | 3,050 | -858 | 1,191 | 2,364 |
| Accrued and other liabilities | 2,727 | -4,799 | 7,508 | 7,718 |
| Contract assets and liabilities | NaN | 5,973 | NaN | NaN |
| Contract liabilities | -2,753 | NaN | 2,166 | NaN |
| Lease liabilities | 686 | 669 | 648 | 1,240 |
| Net cash used in operating activities | -75,170 | -90,496 | 142,214 | -122,816 |
| Purchases of property and equipment, net | 967 | 333 | 42 | 1,993 |
| Purchases of marketable securities | 42,610 | 236,138 | 138,991 | 232,760 |
| Maturities of marketable securities | 162,529 | 138,945 | 180,800 | 360,488 |
| Net cash provided by investing activities | 118,952 | -97,526 | 41,767 | 125,735 |
| Proceeds from issuance of common stock in public offering, net of issuance costs | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock, net of issuance costs-At The Market Offering | NaN | NaN | 24,901 | NaN |
| Proceeds from issuances of pre-funded warrants | NaN | 0 | NaN | NaN |
| Proceeds from espp purchases | NaN | 673 | 0 | 820 |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | -9 | -129 | NaN | 24,984 |
| Proceeds from exercise of common stock options | 1,190 | 1,503 | 384 | 1,544 |
| Net cash provided by financing activities | 1,181 | 2,130 | 301 | 27,348 |
| Net increase in cash, cash equivalents and restricted cash | 44,963 | -185,892 | 184,282 | 30,267 |
| Cash, cash equivalents and restricted cash, at beginning of period | 113,840 | 299,732 | 85,183 | NaN |
| Cash, cash equivalents and restricted cash, at end of period | 158,803 | 113,840 | 299,732 | NaN |
IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA)